European nations not supporting TRIPS waiver move to deal with Covid: Goyal

Unfortunate that some countries putting profits over prudence, said Piyush Goyal on TRIPS waiver proposal

Piyush Goyal, Javadekar
Currently, the proposal initiated by India and South Africa is being discussed at the WTO and has been backed by over 100 countries
Shreya Nandi New Delhi
2 min read Last Updated : Jul 01 2021 | 3:33 AM IST
India is trying to promote a temporary waiver on some sections of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement at the World Trade Organization (WTO), which is a move towards equitable access of vaccines and other medicines to everyone across the world, commerce and industry minister Piyush Goyal said on Wednesday.

Currently, the proposal initiated by India and South Africa is being discussed at the WTO and has been backed by over 100 countries. However, European Union and some other developed nations are not supporting the move. Major pharmaceutical companies have argued that the move can hurt innovation.

“It is unfortunate that some countries are putting profits over prudence...today is not the time even for pharma companies to count their dollars, today is the time for the world to work together...It is myopic strategy that some countries are following,” Goyal said at a virtual event.

Speaking at the India Global forum, the minister said that India is looking at a greater degree of engagement with countries that are ‘democratic in their political system’ and can ‘relate and trust as a partner’.

Towards this, India is working towards greater engagement with countries that believe in transparent rules-based trading mechanisms. India is currently talking to the UK, Australia, Canada and EU for trade deals, and is keen to speed them up.

“We are looking at investments, technology, high quality goods, equipment, machinery. We will be looking at providing high quality technology support to our services & IT sector,” he added.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Piyush GoyalCoronavirus Vaccineintellectual property rightsWorld Trade Organization WTOEuropean Union

Next Story